Printer Friendly

LA JOLLA PHARMACEUTICAL NAMES HEAD OF CHEMICAL OPERATIONS

 LA JOLLA PHARMACEUTICAL NAMES HEAD OF CHEMICAL OPERATIONS
 SAN DIEGO, March 3 /PRNewswire/ -- Douglas A. Livingston, Ph.D., was named associate director of Chemical Processes and Operations at La Jolla Pharmaceutical Co. (LJP), a new position, to head up the manufacturing scale-up and pilot operations for the company's first drug being developed to treat lupus (Systemic Lupus Erythematosus).
 Livingston brings eight years of pharmaceutical industry background to this new position at LJP. His industrial record includes seven years in the Chemical Process R&D division of the Upjohn Co. and one year in the Division of Organic Chemistry at the Burroughs Wellcome Co.
 Livingston earned a bachelor of science in chemistry, with honors, at the University of Washington in Seattle and a Ph.D. in synthetic organic chemistry at Columbia University. He completed his formal training as a post-doctoral fellow at the ETH in Zurich, Switzerland.
 "Filling this position with an individual of Livingston's caliber and pertinent experience is an important step forward, as we scale up to produce our first drug based on our Tolerance Technology," said Joseph Stemler, president and chief executive officer. A clinical trials Food and Drug Administration submission for the lupus treatment is targeted by year end.
 La Jolla Pharmaceutical Co. was established in 1989 to develop products based on its proprietary Tolerance Technology which uses antigen-polymer conjugates to treat antibody-mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 3/3/92
 /CONTACT: Andrew Wiseman of La Jolla Pharmaceutical, 619-452-6600/ CO: La Jolla Pharmaceutical ST: California IN: MTC SU: PER


DM-KJ -- SD002 -- 4342 03/03/92 09:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1992
Words:269
Previous Article:BIOPOOL INTERNATIONAL INC. COMPLETES THE ACQUISITION OF MEDICAL DIAGNOSTIC TECHNOLOGIES INC.
Next Article:MRI MEDICAL DIAGNOSTICS INC. ANNOUNCES EXECUTION OF LETTER OF INTENT TO PURCHASE 100 PERCENT OWNERSHIP OF SIERRA CARDIAC IMAGING INC.
Topics:


Related Articles
DR. THOMAS H. ADAMS ELECTED TO LA JOLLA PHARMACEUTICAL BOARD
ROBERT J. TERNANSKY, Ph.D., JOINS LA JOLLA PHARMACEUTICAL TO HEAD INFLAMMATION PROGRAM
HANS A. de HAAN JOINS LA JOLLA PHARMACEUTICAL AS VICE PRESIDENT, CLINICAL AFFAIRS
LA JOLLA APPOINTS CHIEF OPERATING OFFICER
LA JOLLA PHARMACEUTICAL PROMOTES STEVE ENGLE TO CEO
LA JOLLA PHARMACEUTICAL APPOINTS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT & MARKETING
LA JOLLA PHARMACEUTICAL APPOINTS VICE PRESIDENT OF CLINICAL DEVELOPMENT
Agouron Completes Management Changes

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters